NasdaqGS - Delayed Quote USD
Immunovant, Inc. (IMVT)
14.70
+0.24
+(1.66%)
At close: May 19 at 4:00:01 PM EDT
14.70
0.00
(0.00%)
After hours: May 19 at 4:02:06 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 92.5k | -- | 1979 |
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director | 55k | -- | 1987 |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer | 683.49k | -- | 1963 |
| Mr. Tiago M. Girao CPA | Chief Financial Officer | -- | -- | 1979 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | -- | -- | 1979 |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | -- | -- | 1976 |
| Ms. Lauren Schrier M.B.A. | Vice President of Marketing | -- | -- | -- |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | -- | -- | -- |
| Mr. Andy Deig | Senior Vice President of Strategic Finance | -- | -- | -- |
| Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer | -- | -- | 1969 |
Immunovant, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 207
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Corporate Governance
Immunovant, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 10; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 30, 2025 at 12:30 PM UTC - June 6, 2025 at 12:30 PM UTC
Immunovant, Inc. Earnings Date
Recent Events
Related Tickers
ROIV Roivant Sciences Ltd.
10.84
+0.46%
CYTK Cytokinetics, Incorporated
30.75
-0.81%
CRNX Crinetics Pharmaceuticals, Inc.
30.95
-0.93%
PCVX Vaxcyte, Inc.
32.03
+0.57%
AKRO Akero Therapeutics, Inc.
38.14
-1.88%
XENE Xenon Pharmaceuticals Inc.
30.95
+2.18%
BHVN Biohaven Ltd.
15.75
-1.69%
BBIO BridgeBio Pharma, Inc.
33.69
-0.44%
VERA Vera Therapeutics, Inc.
21.01
-1.13%
SRRK Scholar Rock Holding Corporation
30.16
-1.28%